You just read:

FDA Oncologic Drugs Advisory Committee Votes in Favor of Daiichi Sankyo's Pexidartinib for the Treatment of Select Patients with TGCT, a Rare, Debilitating Tumor

News provided by

Daiichi Sankyo Company, Limited

May 14, 2019, 12:57 ET